title: Juvenile systemic lupus erythematosus in Nigeria.
abstract: Juvenile systemic lupus erythematosus (JSLE) is a complex multisystemic autoimmune disorder of unknown cause. It accounts for about one in five cases of SLE. The tendency for SLE to run a fulminant course when it starts in childhood has made JSLE a potentially more severe disease than adult SLE. Reports of JSLE from sub-Saharan Africa are scanty in spite of the increasing reports of adult SLE. We conducted a 4-year retrospective study of JSLE cases seen at the Lagos State University Teaching Hospital between January 2010 and December 2014. Out of the 12 patients studied, eight were girls and four were boys. All patients had positive antinuclear antibody and extractable nuclear antibody tests. Anti-dsDNA antibody was positive in 10 patients. Eight patients had renal disease while four patients had neuropsychiatric manifestations. Haematological abnormalities and constitutional symptoms were present in all patients. Patients were treated with pulse methylprednisolone, oral prednisolone, hydroxychloroquine and azathioprine. Three patients also received rituximab. In conclusion, JSLE exists in Nigeria and exhibits clinical and immunological characteristics similar to its pattern in other parts of the world. It is, however, diagnosed late and is possibly being underdiagnosed as there is no paediatric rheumatologist in the country.
authors: 1 Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Nigeria.
authors: O O
authors: OO
authors: Adelowo
authors: 1 Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Nigeria.
authors: B H
authors: BH
authors: Olaosebikan
authors: 2 Department of Paediatrics, Lagos State University Teaching Hospital, Ikeja, Nigeria.
authors: B A
authors: BA
authors: Animashaun
authors: 3 Department of Medicine, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
authors: R O
authors: RO
authors: Akintayo
mesh_terms: D000293:Adolescent; D000974:Antibodies, Antinuclear / Q000097:blood*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009549:Nigeria; D012189:Retrospective Studies; D000069283:Rituximab / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000974:Antibodies, Antinuclear; D018501:Antirheumatic Agents; D000069283:Rituximab; D006886:Hydroxychloroquine; D001379:Azathioprine; D008775:Methylprednisolone
keywords: Juvenile; Nigerians; systemic lupus erythematosus